Abstract
Thyroid artery embolization (TAE) is emerging as a potential minimally invasive therapy for benign thyroid hyperplasia (BTH), including multinodular goiter and Graves’ disease, particularly for patients who are poor surgical candidates or who decline surgery. This review summarizes contemporary evidence, technical practices, and areas of consensus and heterogeneity in this technique.